Lemborexant + Placebo
ApprovedRecruiting 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Delayed Sleep Phase Syndrome
Conditions
Delayed Sleep Phase Syndrome
Trial Timeline
Mar 13, 2023 → May 31, 2027
NCT ID
NCT06874855About Lemborexant + Placebo
Lemborexant + Placebo is a approved stage product being developed by Eisai for Delayed Sleep Phase Syndrome. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06874855. Target conditions include Delayed Sleep Phase Syndrome.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07384429 | Approved | Recruiting |
| NCT06874855 | Approved | Recruiting |
| NCT04549168 | Phase 3 | Completed |
| NCT02952820 | Phase 3 | Completed |
Competing Products
8 competing products in Delayed Sleep Phase Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| azathioprine + sirolimus | Astellas Pharma | Approved | 85 |
| Belatacept + Everolimus | Bristol Myers Squibb | Phase 1 | 32 |
| Belatacept + Calcineurin Inhibitor | Bristol Myers Squibb | Phase 2 | 51 |
| ARGX-117 | Argenx | Phase 2 | 49 |
| BG9418 (interferon beta-1a) | Biogen | Pre-clinical | 20 |
| Desflurane + Propofol | Baxter | Approved | 82 |
| Pegcetacoplan | Apellis Pharmaceuticals | Phase 3 | 72 |
| TNX-2110 + TNX-2120 + TNX-2130 + CANDIN + Diluent | Tonix Pharmaceuticals | Phase 1 | 25 |